Clinical trial
A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT03160898 is registered in ClinicalTrials.gov with Cytokinetics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- Cytokinetics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 24, 2017
- Completion date
- March 7, 2019
- Enrollment
- 458 (actual)
- Sites
- 64
Conditions
As the registry lists them; a condition with its own page is linked.